IGHE and allergic disease: Additionally, hIgE mAb could be useful in developing a more patient-friendly allergy immunotherapy by designing hypoallergenic vaccines by specifically altering the symptom-associated IgE epitopes while keeping the treatment-relevant IgG1 and IgG4 epitopes of the target allergen intact.